Quest Plus Gel from Zoetis has recently received approval from the US Food and Drug Administration (FDA) for use in breeding, pregnant and lactating mares, joining Quest Gel as the only FDA-approved de-worming products on the market that treat and control encysted small strongyles and bots in a single dose, and are safe for use in breeding mares.

Both Quest and Quest Plus meeet the individual requirements outlined in the American Association of Equine Practitioners (AAEP) Parasite Control Guidelines. Quest originally launched in 1997 and continues to be a gold standard in equine parasite treatment, and Quest Plus also treats and controls tapeworms. More than 1 million doses of the two de-wormers were sold in the United States in 2015, and more than 9 million doses have been sold in the U.S. since 2004.

“The AAEP recommends treatment for tapeworms in late fall after a hard freeze,” said Kenton Morgan, DVM, Equine Technical Services, Zoetis. “For effective treatment, horse owners should consult with their veterinarian and plan to deworm following a hard freeze in order to target tapeworms.”

To purchase Quest or Quest Plus, please visit your local retailer or veterinarian, and ask your veterinarian to conduct a fecal egg count test prior to purchase. Customers are also encouraged to evaluate their horse’s Individualized Deworming™ needs by visiting Zoetis’ online resources on Individualized Deworming.